News & Reports

Have some news you want to share with the Oregon Bio community?  Fill out our submission form.

BIO Releases Bioscience Economic Development Report and Guide

CHICAGO, IL (Tuesday, April 23, 2013) – The Biotechnology Industry Organization (BIO) released its “Bioscience Economic Development: Legislative Priorities, Best Practices, and Return On Investment” report today at the 2013 BIO International Convention.

The Best Practices Guide is the bioscience industry’s leading comprehensive analysis of state legislative and regulatory initiatives in support of economic development.

At the 2013 BIO International Convention, Tom Corbett (PA), Rick Perry (TX), and Jay Nixon (MO) came together to support the report’s release and discuss bioscience industry […]

April 23, 2013 |

Bausch + Lomb Signs Exclusive License Agreement with Paragon BioTeck for Phenylephrine

Recent U.S. FDA Approval of NDA Clears the Way for Commercialization

MADISON, N.J. and TIGARD, Ore., April 19, 2013 /PRNewswire/ — Bausch + Lomb, the global eye health company, and Paragon BioTeck, Inc. today announced that the companies have entered into a license agreement for Bausch + Lomb to commercialize and distribute Paragon’s phenylephrine in the United States on an exclusive basis beginning this month.

“This agreement with Paragon demonstrates Bausch + Lomb’s commitment to partnering with companies with eye health products […]

April 20, 2013 |

ONAMI Names Len Blackstone High Tech Extension Director

Oregon’s first signature research center strengthens industry connections

Corvallis, OR – April 3, 2013 – Oregon Nanoscience and Microtechnologies Institute announced today that Len Blackstone has been appointed as its new High Tech Extension Director. Blackstone will assist Oregon’s research universities in growing and connecting their technology research and shared user facilities capabilities to small business and industrial clients.

“I’m honored and delighted to be part of ONAMI’s talented team and the outstanding Silicon Forest science and technology community,” commented  Blackstone. “ONAMI […]

April 4, 2013 |

Oregon Translational Research and Development Institute Announces First Bioscience Incubator Client Companies

Local biopharmaceutical companies Aronora and AbSci announced as first client companies in multi-tenant bioscience complex to open spring 2013

PORTLAND, Ore. — Oregon Translational Research and Development Institute (OTRADI) announces local companies Aronora and AbSci as the first clients of the OTRADI Bioscience Incubator (OBI), Oregon’s first and only bioscience-specific accelerator for technology and science companies.
Biopharmaceutical companies Aronora and AbSci will join OTRADI and several others in the 13,000 square-foot bioscience complex when it opens in Portland’s Willamette Wharf building located […]

March 19, 2013 |

Galena Biopharma Acquires Abstral(R) (fentanyl) Sublingual Tablets in U.S., a Novel, Best-in-Class Treatment Approved for Breakthrough Cancer Pain

•    Abstral® was approved in the U.S. in 2011 and is the first and only fentanyl sublingual tablet for the management of breakthrough cancer pain in opioid tolerant patients.
•    Abstral® product launch targeted in the 4th Quarter of 2013.
•    To fund the acquisition and product launch, Galena plans to enter into a non-dilutive debt financing of up to $15 million.

LAKE OSWEGO, Ore., March 18, 2013 (GLOBE NEWSWIRE) — Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing innovative, targeted oncology treatments […]

Galena biopharma receives 2013 Global Frost & Sullivan award for new product innovation for NeuVax (TM)

LAKE OSWEGO, Ore., March 14, 2013 (GLOBE NEWSWIRE) — Galena Biopharma (Nasdaq:GALE), a biopharmaceutical company developing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, announced that independent research firm, Frost & Sullivan, has recognized Galena Biopharma with the 2013 Global Frost & Sullivan Award for New Product Innovation. The Company accepted the honor at the Frost & Sullivan Award Gala, held March 12, 2013 in San Diego, CA.

“We are honored to receive this prestigious […]

March 14, 2013 |

FDA approves first single-lead ICD with atrial sensing

BIOTRONIK’s Lumax DX System Could Help the 50,000 Patients Each Year Who May Benefit from Atrial Sensing, without Pacing Indication

LAKE OSWEGO, Oregon, February 25, 2013 – BIOTRONIK, a leading manufacturer of cardiovascular medical technology, announced the Food and Drug Administration (FDA) has granted final approval for the BIOTRONIK Lumax 740 DX System. This novel device is a first-in-class implantable cardiac defibrillator (ICD) that utilizes a single lead with atrial sensing capabilities.

Single-chamber ICDs are sophisticated electronic devices that utilize a thin flexible […]

March 12, 2013 |

Cost fears lead to health cuts

Health care organizations, bioscience companies prepare for murky future

Portland, March 8, 2013 – By Ben Jacklet; Business Journal staff writer – Portland Business Journal

The hiring freeze at Oregon Health & Science University foreshadows a new era of uncertainty and caution for the state’s health care and bioscience industries.

OHSU last week said it would freeze salaries and adopt other cost-saving measures due to a daunting combination of federal research cuts, health care belt-tightening and skyrocketing pension costs.

“We looked closely at the […]

March 11, 2013 |

Vanguard EMS Completes cGMP/QSR Compliance, FDA Registration

BEAVERTON, OR February 25, 2013 – Vanguard EMS announced today that it has successfully completed the audit for cGMP/QSR compliance and FDA registration as a medical device contract manufacturer.  This accomplishment demonstrates Vanguard’s commitment to excellence in quality systems and management control, including traceability, process validation, and corrective and preventative action.

Vanguard manufactures infant respirators, surgical ultrasound drug delivery systems, and other complex electro-mechanical finished devices.

“This is a logical next step in our services to medical device companies,” says Floyd Sutz, […]

February 27, 2013 |

Taconic and Yecuris Corporation Announce Strategic Marketing Alliance

Taconic to distribute Yecuris Corporation human xenograft FRG™ KO mouse technologies in the US and Europe

Hudson, New York and Portland, Oregon, February 26, 2013 – Taconic and Yecuris Corporation announce the formation of an exclusive marketing and distribution agreement to provide access to the Yecuris FRG™ KO animal portfolio.  The agreement allows Taconic to promote and sell FRG™ primary cell xenograft animal models and HepaCur™ human primary hepatocytes developed by Yecuris Corporation for use in in vivo and in vitro […]

Scientific advisers to the C.D.C. have been discussing the details of federal guidance on who qualifies for a Pfizer-BioNTech booster shot and why. A recommendation by the panel is expected… [...]

NIH vouches for new kidney disease diagnostic that doesn't rely on faulty race-based calculations apark Thu, 09/23/2021 - 14:44 [...]

The discussion, which continues on Thursday, could result in most Americans qualifying for an extra shot, or only a select few. [...]

The most common method of assessing the condition may make Black patients seem less ill than they really are, some experts say. A new report calls for scrapping the formula. [...]

A lawsuit brought on by the Montana Medical Association is challenging the state's ban on employer vaccine mandates. The association, along with other hospitals and patient groups, filed a lawsuit Wednesday… [...]